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Summary
Autoimmune lymphoproliferative syndrome (ALPS) is a
disorder of lymphocyte homeostasis and immunological
tolerance. Most patients have a heterozygous mutation
in the APT1 gene, which encodes Fas (CD95, APO-1),
mediator of an apoptotic pathway crucial to lymphocyte
homeostasis. Of 17 unique APT1 mutations in unrelated
ALPS probands, 12 (71%) occurred in exons 7–9, which
encode the intracellular portion of Fas. In vitro, activated
lymphocytes from all 17 patients showed apoptotic de-
fects when exposed to an anti–Fas agonist monoclonal
antibody. Similar defects were found in a Fas-negative
cell line transfected with cDNAs bearing each of the
mutations. In cotransfection experiments, Fas constructs
with either intra- or extracellular mutations caused dom-
inant inhibition of apoptosis mediated by wild-type Fas.
Two missense Fas variants, not restricted to patients with
ALPS, were identified. Variant A(1)T at the Fas signal-
sequence cleavage site, which mediates apoptosis less
well than wild-type Fas and is partially inhibitory, was
present in 13% of African American alleles. Among the
ALPS-associated Fas mutants, dominant inhibition of
apoptosis was much more pronounced in mutants af-
fecting the intracellular, versus extracellular, portion of
the Fas receptor. Mutations causing disruption of the
intracellular Fas death domain also showed a higher pen-
etrance of ALPS phenotype features in mutation-bearing
relatives. Significant ALPS-related morbidity occurred in
44% of relatives with intracellular mutations, versus 0%
of relatives with extracellular mutations. Thus, the lo-
cation of mutations within APT1 strongly influences the
development and the severity of ALPS.
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Introduction
Autoimmune lymphoproliferative syndrome (ALPS)
(MIM 601859) is a rare disease characterized by chronic
massive, nonmalignant lymphadenopathy and spleno-
megaly; expansion of a normally rare population of
T cells bearing ab-antigen receptors but lacking both
CD4 and CD8 coreceptors (ab double-negative T cells
[abDNTs]); and an in vitro lymphocyte apoptotic defect.
Autoimmune manifestations are nearly always docu-
mented in long-term follow-up of patients with ALPS
(Sneller et al. 1992; Fisher et al. 1995; Rieux-Laucat et
al. 1995). We and others have described mutations in
APT1 (MIM 134637), the gene encoding the Fas/APO-
1/CD95 apoptosis receptor, in patients with ALPS
(Fisher et al. 1995; Rieux-Laucat et al. 1995; Drappa et
al. 1996; Bettinardi et al. 1997; Pensati et al. 1997;
Sneller et al. 1997; Infante et al. 1998; Kasahara et al.
1998). In two studies, homozygous mutations of APT1
led to complete Fas deficiency and severe ALPS (Rieux-
Laucat et al. 1995; Kasahara et al. 1998); in two others
(Bettinardi et al. 1997; Pensati et al. 1997), compound
heterozygous mutations of APT1 were found. In con-
trast, all remaining ALPS-associated APT1 mutations
characterized to date have been heterozygous.
The APT1 gene has nine exons spanning 26 kb (Behr-
mann et al. 1994; Cheng et al. 1995) on chromosome
10q24.1 (Inazawa et al. 1992). Exons 1–5 encode a sig-
nal sequence and three extracellular cysteine-rich do-
mains responsible for binding Fas ligand (FasL). Exon
6 encodes the transmembrane domain of Fas, and exons
7–9 encode the intracellular portion. The Fas death do-
main, encoded by exon 9, is an 80–amino acid structure
conserved in a subset of genes related to tumor necrosis
factor receptor type 1 (TNFR1), including TNFR1,
APT1, DR3, DR4, and DR5 (Singh et al. 1998). The
domain is necessary and sufficient for the death-inducing
activity of the Fas receptor. The functional Fas complex
is a homotrimeric receptor, which, when engaged by ho-
motrimeric FasL, transmits an apoptosis signal via the
death domain. This pathway is crucial in lymphocyte
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homeostasis, serving to delete antigen-driven and au-
toreactive T cell clones (Brunner et al. 1995; Dhein et
al. 1995; Ju et al. 1995).
The critical role of the Fas pathway in lymphocyte
homeostasis and tolerance was first shown in homozy-
gous lpr, lprcg, and gld mice (Davignon et al. 1985; Da-
vidson et al. 1986; Kimura and Matsuzawa 1994). The
lpr and lprcg mice have defects in Fas, and the gld mice
have a defect in FasL (Watanabe-Fukunaga et al. 1992;
Takahashi et al. 1994). These genotypically distinct mice
exhibit the same phenotype: massive lymphocyte accu-
mulation in secondary lymphoid organs, autoimmunity,
hypergammaglobulinemia, and elevated DNTs.
The disease phenotype in lpr and lprcg mice varies with
the background strain, with more severe autoimmunity
occurring on the MRL than the B6 background (Izui et
al. 1984; Ogata et al. 1993). However, even in the same
strain, penetrance is variable. Our previous studies have
shown a similar effect in the human disease, in that some
ALPS family members with APT1 mutations are clini-
cally unaffected (Fisher et al. 1995; Sneller et al. 1997).
In fact, within a given kindred, a wide spectrum of lym-
phoproliferation and autoimmunity can be observed:
Some family members with mutations manifest full-
blown ALPS; some have minimal splenomegaly, adeno-
pathy, or transient autoimmunity; others have only el-
evated abDNTs; and still others are entirely well (Sneller
et al. 1997; Infante et al. 1998).
In these studies, we have sought to examine the role
of APT1 mutations in the development of the ALPS phe-
notype. Herein we characterize APT1 mutations in pre-
viously unreported ALPS kindreds and present the re-
sults of in vitro assays performed to determine to what
extent individual Fas mutants inhibit apoptosismediated
by wild-type Fas. The large number of kindreds studied,
the spectrum of disease expression within them, and the
distribution of their mutations showed a strong rela-
tionship between Fas genotype and penetrance in ALPS.
Patients and Methods
Patient Diagnosis and DNA Isolation
Patients and family members were enrolled, and blood
samples were obtained with informed consent under
protocols approved by the National Institutes of Health
(NIH). Individuals evaluated at the NIH Clinical Center
underwent a review of medical history and records,
physical examination, routine laboratory studies, pe-
ripheral blood lymphocyte (PBL) phenotyping,APT1 ge-
notyping, and in vitro lymphocyte apoptosis assay. For
individuals unable to travel to the NIH, consent was
obtained, samples were mailed, medical records were
reviewed, and telephone interviews were conductedwith
both patient and referring physician. Genomic DNAwas
extracted by standard methods, by use of an ABI 341
nucleic acid purification system (PEApplied Biosystems).
Mutation Analysis
The nine APT1 exons and intron/exon boundaries
were amplified from genomic DNA from each patient
with the primers listed in table 1. PCR was performed
for 10 cycles of 45 s at 94C, 45 s at 68C–59C (i.e.,
decreasing 1C each cycle), and 45 s at 72C, followed
by 25 cycles of 45 s at 94C, 45 s at 58C, and 45 s at
72C. Amplicons were screened for mutations in exons
1–8 by dideoxy fingerprinting (ddF) (Sarkar et al. 1992;
Puck et al. 1997) and in exon 9 by sequence determi-
nation with a Taq cyclist kit (Stratagene). All mutations
were confirmed by reamplification of the mutant exon
and sequencing. To determine the frequency of allelic
variants, we used genomic DNA from a panel of un-
related whites and African Americans. TheA(1)T allele
was analyzed by use of fluorescent sequencing of exon
2 on an ABI 377 DNA sequencer with a dRhodamine
Terminator cycle sequencing kit (PE Applied Biosys-
tems). Exon 4 was analyzed by use of ddF and fluores-
cent sequencing. Statistical analysis of the allele fre-
quencies in white and black populations was done by
use of the x2 test with the Yates correction or, where
appropriate, by Fisher’s exact test.
Penetrance Studies
A total of 37 relatives in families 1, 2, 4, 20, and 34
and a total of 73 relatives in families 3, 5, 17, 26, 27,
29–31, and 45 were screened for APT1 mutations. Pen-
etrance ratios for intracellular versus extracellularAPT1
mutations were analyzed by use of the x2 test along with
the Yates correction. Significant morbidity ratios for in-
tracellular versus extracellular APT1 mutations were an-
alyzed by Fisher’s exact test. P values were reported for
a two-tailed analysis, and levels .05 were considered
significant.
Expression Constructs
RNA was extracted from patient T cells that had been
activated in vitro as described by Fisher et al. (1995).
First-strand cDNA was generated by use of the cDNA
cycle kit (Invitrogen). Full-length Fas cDNA (Genbank
accession number M67454) was amplified as explained
above, but with an extension interval of 1 min 15 s for
40 cycles. Primers used to generate full-length Fas cDNA
are listed in table 1. Fas cDNAs were initially subcloned
into pCR 2.1 (Invitrogen) or pT7Blue-3 (Novagen) and
then subcloned into the pCI vector (Promega) under con-
trol of a cytomegalovirus promoter for expression
studies.
Fas death-domain mutant constructs from patients
29–31 and 33 were made by replacing the 318-bp
Table 1
Primers Used in Analyses of the APT1 Gene
Exona Coding Strandb Anticoding Strandb
Product Size
(bp) Sequencing Primerb
1 TGACTCCTTCCTCACCCTGACTTC gactaagacggggtaagcctccacc 452 CCTCAGGGGCGGGCACT
2 caattttgggtgggttacactggt ttctcatttcagaggtgcatgtca 496 caattttgggtgggttacactggt
3 tcccccattgtatttatatctcattag tgtccttccctttcctgtgt 408 ttgtctgtcatccctctatacttccc
4 cctgcccaccattttcatagtctgc cctaattcttaactctcagtcagtgttacttccc 276 cctgcccaccattttcatagtctgc
5–6 atggcccctaatttacaaagtgcc ctgcagtttgaacaaagcaagaac 394 atggcccctaatttacaaagtgcc, atataaaatgtccaatgttc
7 catgcattctacaaggctgagacc caaacaaaatgaaacaaacaagaaaca 252 aaaaagtaaaaggaagtaacaaaaagc
8 tatttttatttgtctttctctgcttcc ctgaaattggcctattactctaaaggatgc 131 tggcctattactctaaaggatgc
9 aaataaacatggttttcactaatggg ACAAATATGTTGGCTCTTCAGCGC 551 AAATATGTTGGCTCTTCAGCGC, AAGCTTTGGATTTCATTTCT
9 attcccctagtcagctcttcata CATAATCTTAATCTTTCATCCTCTGC 757 GAGATCTTTAATCAATGTGTCA
cDNA CTCAGTACGGAGTTGGGGAAGC CAAACACTAATTGCATATACTCAGAACTG 1,107 CTGCCAAGAAGGGAAGGAG, GGTCCGGGTGCAGTTTATTT
cDNA GGGAAGCGGTTTACGAGTGA TGGGGTTAGCCTGTGGATAGAC 1,545 GACAAAGCCACCCCAAGTTAGA
a cDNA denotes full-length Fas cDNA.
b Intron nucleotides are in lowercase, exon nucleotides in uppercase.
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HincII/ PflMI fragment from the wild-type Fas in pCR
2.1 plasmid with the corresponding mutant fragment.
The A(1)T construct was made by excision and re-
placement of the 209-bp XhoI/StuI fragment from the
wild-type Fas pCI construct. All expression constructs
were sequenced on both strands to verify fidelity. No
additional mutations were observed. Mutant and wild-
type sequences were equally represented in PCR prod-
ucts of full-length Fas from first-strand cDNA as well
as PCR products of Fas genomic DNA.
Expression and Apoptosis
A total of 20 mg of DNA (20 mg of pCI vector alone,
or 10 mg of pCI  10 mg of wild-type Fas, or 10 mg of
pCI 10 mg of mutant Fas, or 10 mg of wild-type Fas 
10 mg of mutant Fas) was transfected into BW5147 mu-
rine thymoma cells by electroporation, as described else-
where (Fisher et al. 1995). BW5147 cells do not express
endogenous Fas or FasL under these culture conditions
(Fisher et al. 1995). Fas mutant 3 (T225P), previously
shown to interfere with apoptosis mediated by wild-type
Fas (Fisher et al. 1995), was included to standardize the
dominant interference assay. Viable cells were purified
with Lympholyte M (Cedarlane) gradients 16 h post-
transfection. An aliquot of gradient-purified cells was
analyzed for Fas expression by use of flow cytometry,
facilitated by staining with anti-Fas monoclonal anti-
body (mAb) UB2 (Immunotech). Cells (9 # 105) were
incubated with or without 2 mg/ml anti-Fas mAb CH11
(Oncor) for 3–4 h to induce apoptosis. Apoptosis was
analyzed with the Apo-Direct kit (Pharmingen). The
fixed cells were stained with propidium iodide to allow
gating on the cycling cells, the population most suscep-
tible to apoptosis (Lenardo 1991). Fluorescein-tagged
UTP was used to label 3′OH ends of DNA (cleavage
fragments generated during apoptosis). For both treated
and control populations, 10,000 events were analyzed
on a FACScan flow cytometer (Becton Dickinson) with
Cell Quest software (Becton Dickinson). Apoptosis in
each cell sample was calculated as ([% CH11-exposed
cells positive for fluorescein-UTP]  [% nonexposed
cells positive for fluorescein-UTP])  (% of cells ex-
pressing Fas). To compare data from numerous killing
assays, the apoptosis for each sample was expressed as
a percentage of apoptosis for cells expressing wild-type
Fas in that assay. The reported apoptosis represents the
average of at least three assays for each mutant, with
standard error of the mean.
Apoptosis assays of patient T cells were performed on
phytohemagglutinin-stimulated T cells maintained in IL-
2 for 21–35 days. Cells (106) were incubated for 5 h
with or without 3 mg/ml CH11 in 1 ml of medium to
induce apoptosis. Apoptosis was analyzed as described
earlier and was expressed as (% CH11-exposed cells
positive for fluorescein-UTP)  (% nonexposed cells
positive for fluorescein-UTP).
Statistical analyses of the results of cotransfections
with wild-type Fas construct versus constructs contain-
ing intracellular or extracellular mutations, and of T cell
apoptosis of normal individuals versus ALPS probands,
were done by two-tailed Student’s t test.
Results
APT1 Mutations
Seventeen distinct APT1 mutations were identified in
affected members of unrelated families enrolled in the
NIH study (fig. 1, numbered symbols above gene dia-
gram). Nine of these mutations have been described else-
where (Fisher et al. 1995; Sneller et al. 1997; Infante et
al. 1998)—as was ALPS family 26, described by Infante
et al. (1998) in a detailed clinical report—and are in-
cluded here because of family member studies and dom-
inant negative studies that are reported herein. Analysis
of DNA from family members showed that, of the eight
newly identified mutations, six were inherited; the in-
heritance in families 24 and 33 was uncertain because
blood samples were not available from both patents.
Twelve (71%) of the 17 APT1 mutations affected the
intracellular region of Fas. The 12 mutant proteins they
encode are predicted to have intact and functional Fas
extracellular and transmembrane domains but to lack
normal death domains. All 12 were expressed equally
well as wild-type Fas in transfection studies (data not
shown). Figure 1 also shows the positions and types of
mutations in patients with ALPS reported by other
groups (symbols below gene diagram). The APT1 mu-
tations in patients whom we have studied are listed in
5′ to 3′ order in table 2. The mutations in ALPS families
1–6, 17, 20, and 26 are described elsewhere (Fisher et
al. 1995; Sneller et al. 1997; Infante et al. 1998); pre-
viously unreported mutations are described in the next
paragraphs.
The ALPS 34 mutation (T131fs) changed the invariant
G residue of the 3′ splice site of intron 4, leading to use
of a cryptic splice site in exon 5 and deletion of the first
22 nucleotides of exon 5. The deletion predicted a frame-
shift and truncation of Fas after 32 missense amino
acids. This predicted protein would lack both the Fas
transmembrane and death domains. The ALPS 45 mu-
tation (K181fs), an 11-bp deletion in exon 7, removed
the first of what is normally a pair of direct ACAGAAA
repeats, as well as four more nucleotides. This deletion
caused a frameshift with a stop codon after ninemissense
amino acids, predicting a Fas protein with intact trans-
membrane and anchoring residues but truncated before
the death domain. The ALPS 24 mutation (P201fs) was
a GrA transition at the last base of exon 8, immediately
Figure 1 Structure of the APT1 gene, showing ALPS-associated mutations, functional variants, and polymorphisms. Exon 9 is expanded to show a helical regions of the intracellular death
domain (Huang et al. 1996). Numbered mutations, protein polymorphism, and functional variant above gene diagram are newly identified herein or were reported elsewhere by NIH investigators
(Fisher et al. 1995; Sneller et al. 1997; Infante et al. 1998). Mutations and other DNA polymorphisms identified by other groups are shown below gene diagram: A, Rieux-Laucat et al. (1995); B,
Drappa et al. (1996); C, Bettinardi et al. (1997); D, Kasahara et al. (1998); E, Fiucci and Ruberti (1994); and F, Pensati et al. (1997).
Table 2
APT1 Mutations, Phenotype, and Penetrance in 17 Families with ALPS
MUTATION PROBAND PHENOTYPE PENETRANCE IN RELATIVES
EXON OR
INTRON
Nucleotide
(mRNA)
Change
Protein
Change
PROBAND
NUMBER AGEa Autoimmunityb Lymphoproliferationc
%
abDNTsd
%
Apoptosise
Proportion
with ALPS
Featuresf
Number with
Significant
Morbidityg
Exon 3 413CrA C57X 20 3 years GBS L, HSM 4–9 0 2/7 0
Exon 3 429delG D62fsh,i 1 4 mo ITP L, HSM 14–28 6 0/3 0
Intron 3 IVS32insT (skip exon 3
or exons 3 and 4) P49del46,j P49fsk 2 18 mo GN, ITP, PBC L, HSM 16–49 Defectivel 0/3 0
Intron 4 IVS4(-1)GrC (cryptic splice
638del22) T131fsm 34 2 years HA L, SM 5 1 0/1 0
Intron 6 IVS6(-2)ArC (cryptic
splice ins 72) V174fsn 4 2 years UR L, HSM 2–7 Defectivel 1/3 0
Exon 7 779del11 K181fso 45 4 years ITP L, SM 10–12 13 6/6 4
Exon 8 870GrA (skip exon 8) P201fsp 24 11 mo ITP L, HSM 18 7 NAq NAq
Exon 9 915ArC T225P 3 5 years HA, ITP, AN L, SM 6–15 1 4/4 3 (2 with LY)
Exon 9 916CrA T225K 27 5 years L, HSM 8–18 0 1/3 0
Exon 9 943GrA R234Q 29 2 years L, HSM 2 0 2/2 1
Exon 9 943GrC R234P 31 9 mo HA, ITP L, HSM 8–36 5 8/8 5
Exon 9 964CrA A241D 6 4 mo HA L, SM 5–13 1 De novo mutation De novo mutation
Exon 9 973ArT D244V 26 Birth HA L, SM 1–2 0 10/10 3 (1 with LY)
Exon 9 1011CrT Q257X 5 2 mo HA, ITP, AN L, SM 8–18 Defectivel 1/3 0
Exon 9 1020CrT Q260X 33 11 mo HA L, SM 6–9 0 NAq NAq
Exon 9 1074delT L278Xn 30 1 year GN, HA, ITP, AN L, SM 7–19 5 4/4 1
Exon 9 1123TrG I294S 17 4 mo HA, AN L, HSM 11–24 5 2/3 2
a Age  age at presentation.
b All had autoantibodies. Additional overt autoimmune diseases were: GBS  Guillain-Barre´ syndrome, ITP  immune-mediated thrombocytopenic purpura, GN glomerulonephritis,
PBC  primary biliary cirrhosis, HA  hemolytic anemia, UR  urticarial rash, and AN  autoimmune neutropenia (i.e., neutropenia persisting after splenectomy associated with normal
myeloid precursors in the marrow).
c L  lymphadenopathy, HSM  hepatosplenomegaly, and SM  splenomegaly.
d CD3abCD4CD8 cells/CD45bright CD14 cells in the lymphocyte gate, expressed as a range when multiple assays were performed (normal value !1%).
e Normal range standard deviation.52% 12%
f Features include adenopathy, abnormal autoantibodies in serum, autoimmunity, and elevated abDNT concentrations.
g One or more of the following: splenectomy, autoimmune disease requiring treatment, or lymphoma (LY).
h Frameshifts; the number refers to the last normal amino acid codon.
i A total of 34 missense amino acid codons.
j In-frame deletion of 46 amino acids.
k A total of 38 missense amino acid codons.
l Sneller et al. (1997); determination by assay described by Fisher et al. (1995).
m A total of 32 missense amino acid codons.
n Frameshift to an immediate stop.
o Nine missense amino acid codons.
p Three missense amino acid codons.
q Not available.
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Table 3
APT1 Mutation and Clinical Phenotype for Fas Protein Polymorphic Variants
MUTATION CLINICAL PHENOTYPE
EXON
Nucleotide
Change
Protein
Change
PROBAND
NUMBER
Auto-
immunity
Lympho-
proliferation
%
abDNTsa
% Lymphocyte
Apoptosisb
2 240GrA A (1)T (signal
sequence)
29, 33 NAc NAc NAc NAc
4 559CrT T106I 33 Noned Noned .2d 49.4d
a CD3 abCD4/CD8 cells /CD45bright CD14 cells in the lymphocyte gate (normal value !1%).
b Normal range standard deviation.52% 12%
c Not available (available individuals with the 240GrA change had death-domain mutations as well).
d Phenotype of a mutation 33 negative, polymorphic variant heterozygote from ALPS family 33.
preceding the invariant GT of the 5′ splice site consensus.
This G residue is conserved in 77% of 5′ splice sites
(Cooper and Krawczak 1995, pp. 239–260). Consistent
with previously analyzed mutations in other genes (Coo-
per and Krawczak 1995, pp. 239–260), mutant cDNA
sequenced from patient 24 lacked exon 8. The resulting
frameshift predicted a truncation after 3 missense amino
acids, and thus no death domain was present.
Four new mutations, T225K, R234Q, R234P, and
Q260X, in patients 27, 29, 31, and 33, respectively, were
point mutations within the Fas death domain. The first
three were missense mutations that caused nonconser-
vative amino acid substitutions. The T225K and T225P
(Fisher et al. 1995) mutations at Fas nucleotides 915
and 916 suggest that this codon is a mutational hot spot
in APT1. In addition, R234Q and R234P were encoded
by different point mutations at nucleotide 943; these
mutations, together with a previously reported nucleo-
tide 942 Fas truncation (Drappa et al. 1996), mark the
942-943 CpG dinucleotide as a second mutational hot
spot in APT1. The ALPS 30 mutation (L278X) was a
1-bp deletion, and the deleted T was part of an ATT
repeat. This frameshift predicted an immediate stop.
Both Q260X and L278X predicted Fas proteins with
truncated death domains.
Two APT1 missense mutations were found in more
than one individual (table 3). An alanine to threonine
change, A(1)T (fig. 1, V, above exon 2), in the last
residue of the Fas signal sequence, occurred because of
a GrA transition; and a threonine to isoleucine (T106I)
substitution (fig. 1, p, above exon 4) was located in the
second extracellular cysteine-rich domain of Fas. By pa-
tient cDNA sequencing and by sequencing exon 2 in
additional members of ALPS families 29 and 33, it was
determined that the A(1)T substitution resided on the
same allele as the death-domain mutations (R234Q and
Q260X) in both cases. Interestingly, patient 33 had the
T106I substitution on one Fas allele and A(1)T/
Q260X on the other allele. T106I was also found in an
unrelated individual who did not have ALPS. All three
individuals bearing these substitutions were of African
American descent. Therefore, we determined the fre-
quency of these alleles in black and white individuals.
The A(1)T substitution was found in 13% (15/116)
of black alleles but only 1% (1/90) of white alleles
( ). The T106I substitution was found in 2% (2/P ! .005
116) of black alleles and was not observed in 102 white
alleles (not significantly different).
Aside from previously recognized silent nucleotide
polymorphisms (fig. 1, p, below exons 3 and 7) (Fiucci
and Ruberti 1994), no other alterations of the APT1
sequence were found by the sensitive ddF screening
method in genomic DNA from patients with ALPS or
their relatives. In addition, none of these mutations was
seen by single-strand conformation polymorphism anal-
ysis of APT1 in 104 alleles from unrelated white indi-
viduals (Fisher et al. 1995; and data not shown); by ddF
or sequencing of APT1 in 18 alleles from unrelatedwhite
individuals (data not shown); or by ddF of exon 9 in
106 alleles from unrelated black individuals (data not
shown).
Apoptosis
As shown in table 2, an in vitro apoptosis defect was
demonstrable in T cells from every proband. The mean
apoptosis induced by anti-Fas mAb in activated T cells
maintained in IL-2 was , whereas cells from3% 4%
11 healthy control subjects tested in the same assay av-
eraged ( ).52% 12% P ! .001
Apoptosis mediated by mutant Fas molecules was
studied by transfecting BW5147 murine thymoma cells
with expression constructs containing human mutant
Fas cDNAs, wild-type Fas cDNA, or pCI vector alone.
An example of one such apoptosis experiment is shown
in figure 2. Cleavage of cellular DNA into small frag-
ments (DNA laddering), a hallmark of apoptosis, pro-
duces an increase in free 3′OH DNA ends, detected by
fluorescein-UTP incorporation into DNA termini by ter-
minal deoxynucleotidyl transferase. The increased flu-
orescence induced by anti-Fas treatment in wild-type Fas
transfectants (fig. 2B) was not seen in transfectants with
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Figure 2 FACS analysis of apoptosis, using histograms that de-
pict the shift in fluorescence as fluorescein-UTP is incorporated into
DNA termini. Cell numbers are on the y-axis, fluorescence intensity
on the x-axis. Control BW5147 cells without anti-Fas mAb, light trac-
ing; experimental BW5147 cells with anti-Fas mAb, bold tracing.
Transfected plasmid constructs are indicated for each experiment.
pCI alone (fig. 2A) or in transfectants with a mutant
construct A(1)T/Q260X (fig. 2C).
Apoptosis achieved in cells transfected with mutant
Fas constructs was very low compared with that in cells
receiving wild-type Fas (fig. 3), with a mean only 8%
of that of the wild-type killing level for all 14 mutant
alleles. Transfections with constructs containing alleles
A(1)T/R234Q and A(1)T/Q260X from patients 29
and 33 did not differ significantly in apoptosis from
transfections using constructs with R234Q and Q260X
mutations on an otherwise wild-type Fas background.
A transfected allele with the T106I variation (fig. 3, right
hatched bar) was not significantly different from wild-
type Fas in ability to mediate apoptosis. However, apop-
tosis mediated by an allele with the A(1)T variant (fig.
3, left hatched bar) was only that of wild-52% 11%
type Fas apoptosis.
To study the inhibitory effect of mutant Fas proteins
on apoptosis mediated by wild-type Fas, we induced
apoptosis with anti-Fas mAb in BW5147 cells cotrans-
fected with 10 mg of wild-type and 10 mg of mutant
cDNA. The assay developed by Fisher et al. (1995) was
adapted to use UTP incorporation, as described. If we
assume equal expression of mutant and wild-type Fas
proteins, the fraction of all Fas trimers that are assem-
bled exclusively of normal Fas protein would be⅛ ([½]3).
An example of dominant inhibition of apoptosis is
shown in figure 2D, in which cells were cotransfected
with wild-type Fas and A(1)T/Q260Xmutant Fas con-
structs. The addition of the mutant allele attenuated the
apoptotic shift seen with wild-type Fas alone (fig. 2B).
All Fas mutants tested exerted a dominant negative effect
on apoptosis by this assay (fig. 4).
Addition of the constructs with extracellular Fas mu-
tants C57X, D62fs, and T131fs reduced apoptosis me-
diated by wild-type Fas to an average level 27% that of
wild type alone (fig. 4, white bars). All but one of the
intracellular mutant alleles had an even more pro-
nounced dominant negative effect on apoptosis. The sin-
gle exception was Fas mutant T225K, which, on co-
transfection, diminished wild-type apoptosis by only
33% (fig. 4), a smaller decrement in apoptosis than was
seen with any of the 11 other ALPS-associated delete-
rious Fas death-domain mutants tested. It is intriguing
that the effect of this mutant was so mild, because it
occurred at the same position as T225P, which had a
severe effect on function. The father in this ALPS kin-
dred, who also carries the T225K mutation, had the
same degree of impairment in lymphocyte apoptosis as
the proband (data not shown). Preliminary biochemical
studies indicate that T225K has a milder effect on in-
tracellular signal transduction than the other mutants
(R. Siegel, D. Martin, and M. Lenardo, unpublished
data). When we excluded T225K, which appeared to
have a distinct molecular mechanism, the remaining in-
tracellular mutants, on average, caused a 91% reduction
in apoptosis mediated by wild-type Fas. These 11 intra-
cellular mutants blocked Fas-mediated apoptosis signif-
icantly more than did the extracellular mutants (P 
)..02
Dominant negative assays were also used to determine
whether the Fas polymorphic variants A(1)T and
T106I noted in patients 29 and 33 caused any reductions
in apoptosis when present in the heterozygous state.
Cells were cotransfected with combinations of wild-type
and variant Fas alleles with and without the death-do-
main dominant mutations R234Q and Q260X. A co-
linear A(1)T substitution did not alter the dominant
negative effect that R234Q or Q260X had on apoptosis
(fig. 4). Cotransfections with A(1)T/Q260X  T106I
plasmids also did not differ from cotransfections with
Q260Xwild-type Fas or A(1)T/Q260Xwild-type
Fas with respect to dominant inhibition of apoptosis.
However, the construct containing only the A(1)T sub-
stitution reduced apoptosis mediated by wild-type Fas
by 41%. In contrast, the T106I allele did not alter apop-
tosis mediated by wild-type Fas.
Penetrance
All available at-risk relatives of patients with ALPS
were invited to be tested for Fas defects. Fourteen of the
17 ALPS probands had relatives who shared their APT1
mutations. Phenotypic features of ALPS, including ad-
enopathy, significant titers of autoantibodies, overt au-
toimmunity, and elevated ab DNTs, were sought by his-
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Figure 3 Apoptosis of BW5147 cells, mediated by transfected mutant Fas or Fas polymorphic variants. Twenty micrograms of DNA was
used in each of at least three experiments. Gray area denotes control, white area denotes extracellular mutants, black area denotes intracellular
mutants, and hatched area denotes protein polymorphic variants. Mutant Fas apoptosis was normalized to wild-type Fas apoptosis (100%) for
each assay (wild-type values before adjustment were ; ). Bars show mean  standard error.82% 5% n  10
tory and examination, review of medical records,
physician interviews, and laboratory tests. The most
striking observation was that penetrance of one or more
ALPS features was 88% (38/43) for individuals with
intracellular mutations versus 18% (3/17) for individ-
uals with extracellular mutations ( ; table 2). OfP ! .001
five families with extracellular mutations and additional
members with an APT1 mutation (1, 2, 4, 20, and 34),
only two families included members other than the pro-
bands who displayed any features of ALPS. In contrast,
all nine families with intracellular mutations and addi-
tional members with an APT1 mutation (3, 5, 17, 26,
27, 29–31, and 45) included individuals besides the pro-
band who displayed features of ALPS. Two kindreds
(families 3 and 26) with 100% penetrance of ALPS fea-
tures included mutation-positive members with lym-
phoma. In addition, ALPS-related significant morbidity
(patients undergoing splenectomy, having autoimmune
disease requiring treatment, or developing lymphoma)
was present in 44% (19/43) of relatives with intracellular
APT1 mutations versus none of the relatives (0/17) with
extracellular mutations ( ).P ! .001
Discussion
A cohort of patients with ALPS and their relatives has
enabled us to discover a relationship between genotype
and clinical phenotype in kindreds with APT1 muta-
tions. Although probands were recognized because of
significant morbidity, disease expression can vary within
a family (Fisher et al. 1995; Infante et al. 1998). There-
fore, identification of an APT1 mutation cannot alone
precisely predict the severity of disease. However, both
a greater clinical penetrance and increased rates of ALPS-
related morbidity were found in relatives with intracel-
lular versus extracellular mutations. Thus, increased
dominant negative effect on apoptosis in the intracellular
versus extracellular Fas mutants may contribute to in-
creased penetrance. Our data show that, for some in-
tracellular APT1 mutations, penetrance is extremely
high. Individuals in these families who carry APT1 mu-
tations but are free of significant morbidity may have
genetic factors that protect against the ALPS phenotype.
We have identified and functionally characterized 17
APT1 mutations causing ALPS, 8 of which were not
previously reported. Exon 9, which encodes the Fas
death domain, was found to harbor 16 (59%) of the 27
APT1 mutations causing ALPS, both in our cohort and
in reports published elsewhere (fig. 1). Mutations re-
sulting in cell-surface expression of Fas proteins without
a normal death domain account for 19 (70%) of all of
the 27 published APT1 mutations causing ALPS (fig. 1).
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Figure 4 Apoptosis of BW5147 cells by cotransfected mutant and wild-type Fas or cotransfected Fas protein polymorphic variant and
wild-type Fas. Twenty micrograms of DNA was used in each of at least three experiments. Gray area denotes control, white area denotes
extracellular mutants, black area denotes intracellular mutants, and hatched area denotes protein polymorphic variants. Apoptosis mediated
by mutant Fas was normalized to wild-type Fas apoptosis (100%) for each assay (wild-type values before adjustment  ; ).83% 6% n  14
All of the 17 Fas mutant proteins we studied were
severely impaired in their ability to mediate apoptosis,
and all interfered with apoptosis mediated by wild-type
Fas in an in vitro cotransfection assay. As a group, the
intracellular Fas mutants interfered with apoptosis me-
diated by wild-type Fas more strongly than did the ex-
tracellular mutants, suggesting different mechanisms of
dominant negative interference. Three of the APT1 mu-
tant alleles (C57X, D62fs, and T131fs ) predicted a pu-
tative soluble Fas protein. Several naturally occurring
splice variants of Fas are known to produce truncated
soluble Fas (Cascino et al. 1995; Liu et al. 1995; Papoff
et al. 1996). Some of these proteins can interfere with
apoptosis in vitro, possibly by hindering Fas-FasL bind-
ing, and may be involved in the physiologic regulation
of Fas activity (Cascino et al. 1995; Liu et al. 1995). A
common Fas splice variant is the deletion of exon 6,
which eliminates the sequence encoding the transmem-
brane domain, resulting in soluble Fas. Messenger RNA
encoding this Fas Dexon 6 variant may constitute 50%
of the Fas mRNA in resting lymphocytes (Liu et al.
1995). However, the mRNA encoding other soluble Fas
proteins accounts for only 5% of the total Fas mRNA
in peripheral blood mononuclear cells, and for !1% of
the Fas mRNA in stimulated PBL (Liu et al. 1995). The
mutant Fas mRNA from our patients with ALPS who
had extracellular mutations appeared stable, in that mu-
tant cDNA clones were recovered with the same fre-
quency as wild-type clones. The extracellular mutants
may have disrupted wild-type Fas function by interfer-
ence with Fas translation or intracellular processing.
However, although mutants C57X, D62fs, and T131fs
showed dominant interference with apoptosis mediated
by wild-type Fas, they did not interfere with expression
of wild-type Fas in our in vitro assays. Possible methods
of apoptotic interference by extracellular mutants are
incorporation into a Fas trimer that cannot transduce a
signal or binding to, and blocking, anti-Fas mAb (or, in
patients, FasL). The dominant effect on apoptosis seen
for these putative soluble proteins implies that a simple
haploinsufficiency of Fas did not cause ALPS in these
patients. Interestingly, the Fas 4 mutation (V174fs),
which has been shown to have a dominant negative ef-
fect on apoptosis (Fisher et al. 1995), potentially uses
two methods of dominant negative interference with
apoptosis: secretion of soluble protein and cell-surface
expression of truncated protein. In vitro transfection of
this mutant resulted in only 20%–30% of the cell-sur-
face expression achieved by transfecting wild-type Fas
(Fisher et al. 1995; and data not shown). Although the
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Fas 4 mutant has a transmembrane domain, it lacks any
cytoplasmic amino acids to anchor the protein in the
cell membrane. Because it is likely that the cell-surface
expression is transient, even in vivo, ALPS family 4 was
considered to be functionally like families with extra-
cellular mutations, for penetrance analyses.
The smallest dominant inhibitory effect on apoptosis
exerted by any of the mutants was seen with Fas mutant
T225K. Fas mutant T225P, at the same residue, is a
potent dominant inhibitor of apoptosis, but proline res-
idues are known to disrupt a helices.Whereas the T225P
death domain showed global disruptions by nuclear
magnetic resonance structural analysis, the structure of
the T225K death domain closely resembles that of wild-
type Fas (D. Martin andM. Lenardo, unpublished data).
Further biochemical analysis of mutant T225Kmay clar-
ify the molecular mechanism by which it impairs
apoptosis.
One of the two protein polymorphic variants of Fas
that we identified, A(1)T, interferedwith apoptosisme-
diated by wild-type Fas in transfection assays. However,
unlike the ALPS-associated Fasmutants, whichmediated
apoptosis, on average, only 8% as well as wild-type Fas,
the A(1)T variant mediated apoptosis 52% as well as
the wild-type Fas. There have been several reports of a
signal-sequence mutation causing disease (Arnold et al.
1990; Watzke et al. 1991; Ito et al. 1993). In two
cases—mutation of preprovasopressin leading to famil-
ial central diabetes insipidus and mutation of prepro-
parathyroid hormone leading to familial isolated hy-
poparathyroidism—dominant negative effects of the
mutant proteins on wild-type functionwere seen (Arnold
et al. 1990; Ito et al. 1993). Interestingly, the prepro-
vasopressin mutation encoded the same amino acid
change as did our A(1)T Fas variant. Processing studies
of this signal-sequence mutant in preprovasopressin
showed that the cleavage of its signal was reduced to
25% of the wild type’s. Suggested pathologic mecha-
nisms are accumulation of preprovasopressin in the en-
doplasmic reticulum or interference with protein pro-
cessing (Ito et al. 1993). The Fas A(1)T variant appears
to have normal processing, in that it was expressed on
the cell surface as fully as the wild-type Fas (data not
shown). Cleavage of the Fas signal sequence may have
occurred at an alternative site, leading to Fas trimers
that are less effective at transmitting a death signal.
The effect of the Fas A(1)T variant in individuals
heterozygous or homozygous for this allele is potentially
important, since several autoimmune diseases, including
sarcoidosis (Arnold 1993), systemic lupus erythematosus
(SLE) (Schur 1993), and Graves’ disease (Yanagawa and
de Groot 1996), occur more frequently in blacks than
in whites. Because the A(1)T variant allele is more
common in the black population, studies are ongoing to
determine whether this allele is associated with any of
these diseases. A promoter polymorphism of tumor ne-
crosis factor a (TNF-a), which initiates the TNFR1
apoptotic pathway, has been associated with SLE in
blacks (Sullivan et al. 1997). This polymorphism is as-
sociated with increased TNF-a production and also oc-
curs more frequently in whites with SLE, dermatitis her-
petiformis, alopecia areata, and rheumatoid arthritis
(Messer et al. 1994; Wilson et al. 1994; Danis et al.
1995a, 1995b; Galbraith and Pandey 1995).
Mutations in APT1 and consequent dysfunction of
the Fas-mediated apoptotic pathway may predispose in-
dividuals to lymphoma, leukemia, and myeloma, as well
as other types of cancer. We have noted three cases of
lymphoma in two of our ALPS kindreds (Sneller et al.
1997; Infante et al. 1998). Landowski et al. (1997) found
five Fas death-domain mutations in bone marrow cells
from 54 patients with multiple myeloma, and Beltinger
et al. (1998) found two Fas mutations in T-lineage acute
lymphoblastic leukemia blasts from 81 patients. Three
patients with ALPS with other cancers have been re-
ported (Drappa et al. 1996; Kasahara et al. 1998). Ab-
normal Fas function may allow transformed cells to sur-
vive and become neoplastic. However, the relative risk
of neoplasia remains to be determined.
Because many family members of ALPS probands har-
bored an APT1 mutation but showed no overt disease,
other factors must also contribute to the pathogenesis
of ALPS. Moreover, six individuals fitting the clinical
definition of ALPS—lymphoproliferation, autoimmun-
ity, 11% ab DNTs, and in vitro lymphocyte apoptosis
defect—did not have any detectable mutations in the
APT1 gene (Sneller et al. 1997; and data not shown).
The Fas pathway is initiated by engagement of trimeric
Fas ligand with the extracellular portion of trimeric Fas,
followed by intracellular recruitment of Fas-associating
protein with death domain (PADD) and activation of a
protease cascade starting with caspase 8 (FLICE,MACH
1) (Nagata 1997). Alterations in any of these proteins
or in related members of the TNFR1 apoptotic pathway
or the BCL-2 family could combine with Fas mutations
or act independently to contribute to the phenotype of
ALPS.
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